Fredun Pharmaceuticals Ltd.
1,391.20
INR
+19.70
(+1.44%)
ISIN
INE194R01017
Return %
Stock
S&P 500
1Y
151.30
14.20
3Y
408.67
81.12
5Y
750.11
68.34
Capital Structure
INR
•
in mil. unless spec.Working Capital
INR
•
in mil. unless spec.Growth Rates
INR
•
in mil. unless spec.Quarterly Revenue
INR
•
in mil. unless spec.Quarterly Earnings Per Share
INR
•
in mil. unless spec.Quarterly Dividends Per Share
INR
•
in mil. unless spec.Company Description
- CEO
- Daulat Nariman Medhora
- Full Time Employees
- 736
- Sector
- Health technology
- Industry
- Pharmaceuticals: major
- Address
- Urmi Estate Mumbai MA India 400013
- IPO Date
- Mar 17, 2016
- Website
- fredungroup.com
- Similar Companies
- Business
- Fredun Pharmaceuticals Limited is an India-based pharmaceutical company engaged in the manufacturing and marketing of pharmaceutical formulations, dietary and herbal supplements, nutraceuticals, cosmeceuticals, and animal healthcare products. Founded in 1987 and headquartered in Mumbai, the company operates across multiple segments including allopathic formulations marketed under the Fredun Gx brand, nutraceuticals and dietary supplements under the Fredun Nutrition brand, and pet healthcare products under the Freossi brand. Its cosmeceutical division, operating under Bird N Beauty (BNB) and Beautyfred brands, focuses on skincare and personal care products. The company’s product portfolio includes a broad range of allopathic drugs such as analgesics, antidiabetics, antihypertensives, antivirals, antifungals, and other therapeutic categories, along with surgical products, active pharmaceutical ingredients (APIs), direct compressible granules, pellets, and niche healthcare products. Fredun’s geographic footprint spans India, Africa, Southeast Asia, the Commonwealth of Independent States (CIS), and Latin America. Recent major developments include the strategic acquisition of Wagr.ai, a pet tech platform, marking Fredun’s entry into India's first truly neutral online marketplace for pet products and services, which is set for relaunch in Q4 FY 2025-26. This acquisition aligns with Fredun’s vision to build a comprehensive ecosystem for pet care commerce in India. Additionally, Fredun is expanding its manufacturing capacity with a cutting-edge functional foods plant for pets at Palghar, Maharashtra, expected to commence operations by Q3 FY26, to cater to the growing pet care industry demand. The company also reported a robust Q1 FY26 performance with a 64% increase in net profit and a strong order book exceeding ₹200 crore, underscoring solid revenue visibility. Fredun continues to strengthen its market position through diversification across generics, cosmeceuticals, nutraceuticals, mobility aids, and animal healthcare products, supported by new board appointments and operational enhancements. Fredun Pharmaceuticals maintains a strong export presence with products distributed in emerging markets, emphasizing innovation in dietary supplements, healthcare formulations, and pet care solutions. The company’s ongoing investments in manufacturing capacity and technology-driven platforms reflect its strategic focus on expanding its product offerings and market reach within India and international markets. This comprehensive product and operational strategy positions Fredun Pharmaceuticals as a significant player in the pharmaceutical and healthcare sectors, with a diversified portfolio that includes healthcare products for humans and animals, supported by recent strategic acquisitions and capacity expansions that fuel ongoing growth and competitiveness in the global market.